Related Experiment Video
Updated: May 18, 2026

Hypothalamic Kisspeptin Neurons as a Target for Whole-Cell Patch-Clamp Recordings
Published on: March 17, 2023
Neurotransmissions of antidepressant-like effects of kisspeptin-13
M Tanaka1, K Csabafi, G Telegdy
1Neuroscience Research Group of the Hungarian Academy of Science, University of Szeged, Szeged, Hungary.
Abstract:
Kisspeptins are G protein-coupled receptor ligands originally identified as human metastasis suppressor gene products that have the ability to suppress melanoma and breast cancer metastasis and which have recently been found to play an important role in initiating the secretion of gonadotropin-releasing hormone at puberty. In the brain, the gene is transcribed within the hippocampal dentate gyrus. Kisspeptin-13, one of the endogenous isoforms, consists of 13 amino acids. In this work, antidepressant-like effects of kisspeptin-13 were studied and the potential involvement of the adrenergic, serotonergic, cholinergic, dopaminergic and gabaergic receptors in its antidepressant-like effects was investigated in a modified forced swimming test (FST) in mice. The mice were pretreated with a nonselective α-adrenergic receptor antagonist, phenoxybenzamine, an α(1)/α(2β)-adrenergic receptor antagonist, prazosin, an α(2)-adrenergic receptor antagonist, yohimbine, a β-adrenergic receptor antagonist, propranolol, a mixed 5-HT(1)/5-HT(2) serotonergic receptor antagonist, methysergide, a nonselective 5-HT(2) serotonergic receptor antagonist, cyproheptadine, a nonselective muscarinic acetylcholine receptor antagonist, atropine, a D(2),D(3),D(4) dopamine receptor antagonist, haloperidol, or a γ-aminobutyric acid subunit A receptor antagonist, bicuculline. The FST revealed that kisspeptin-13 reversed the immobility, climbing and swimming times, suggesting antidepressant-like effects. Phenoxybenzamine, yohimbine and cyproheptadine prevented the effects of kisspeptin-13 on the immobility, climbing and swimming times, whereas prazosin, propranolol, methysergide, atropine, haloperidol and bicuculline did not modify the effects of kisspeptin-13. The results demonstrated that the antidepressant-like effects of kisspeptin-13 in a modified mouse FST are mediated, at least in part, by an interaction of the α(2)-adrenergic and 5-HT(2) serotonergic receptors.
Insights
Kisspeptin-13 exhibits antidepressant-like effects in mice by interacting with alpha-2 adrenergic and serotonin 5-HT2 receptors. These findings suggest novel therapeutic targets for depression treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Endocrinology
Background:
- Kisspeptins are ligands for G protein-coupled receptors, known for metastasis suppression and regulating gonadotropin-releasing hormone secretion.
- Kisspeptin-13, a 13-amino acid isoform, is found in the brain, specifically the hippocampal dentate gyrus.
Purpose of the Study:
- To investigate the antidepressant-like effects of kisspeptin-13 in a mouse model.
- To explore the involvement of adrenergic, serotonergic, cholinergic, dopaminergic, and GABAergic receptors in these effects.
Main Methods:
- A modified forced swimming test (FST) was used to assess antidepressant-like activity in mice.
- Mice were pretreated with various receptor antagonists including adrenergic, serotonergic, cholinergic, dopaminergic, and GABAergic antagonists.
Main Results:
- Kisspeptin-13 significantly reduced immobility, climbing, and swimming times in the FST, indicating antidepressant-like effects.
- The antidepressant-like effects of kisspeptin-13 were blocked by phenoxybenzamine (nonselective alpha-adrenergic antagonist), yohimbine (alpha-2 adrenergic antagonist), and cyproheptadine (nonselective 5-HT2 serotonergic antagonist).
- Prazosin, propranolol, methysergide, atropine, haloperidol, and bicuculline did not alter the effects of kisspeptin-13.
Conclusions:
- The antidepressant-like effects of kisspeptin-13 are mediated, at least partly, through interactions with alpha-2 adrenergic and 5-HT2 serotonergic receptors.
- These findings highlight a potential role for kisspeptin-13 in modulating mood and suggest it as a target for antidepressant drug development.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
G-protein Coupled Receptors
Neurotransmitters
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...

